<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074147</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH_2019_04</org_study_id>
    <nct_id>NCT05074147</nct_id>
  </id_info>
  <brief_title>Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)</brief_title>
  <acronym>CHRONOS-2</acronym>
  <official_title>Three Weeks Versus Six Weeks Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis : a Multicenter, Randomized, Open-label and Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tourcoing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical study is to compare the efficacy and tolerance of 3 versus 6 weeks&#xD;
      of antibiotherapy in patients with diabetic foot osteomyelitis treated medically.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The fight against multi-drug resistant bacteria is a global matter and a major health public&#xD;
      issue. The excessive exposure of microorganisms to drugs increases their ability to develop&#xD;
      survival mechanisms, causing an emerging threat and a health challenge.&#xD;
&#xD;
      Several recent studies showed that 18-35% of patients with diabetic foot infections harbored&#xD;
      multiply drug-resistance to organisms (MDRO), the most common is Staphylococcus aureus&#xD;
      (MRSA). Hospitalization, surgical procedures and long antibiotic therapy induce the&#xD;
      development of MDRO or MRSA In diabetic foot, Osteomyelitis (DFO) is a well recognize risk&#xD;
      factor for major amputation and mortality rates that occurs in more than 20% of moderate&#xD;
      infections and 50% to 60 % of severe infections. In this context, the aim of this study is to&#xD;
      evaluated that reducing time of antibiotic administration (3 weeks) is not substantially&#xD;
      worse than the current treatment guidelines (6 weeks) in DFO managed nonsurgically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of diabetic foot osteomyelitis at the end of follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>Remission is defined as one of following events :&#xD;
No relapse of infection at the initial or a contiguous site leading to make a new antibiogram.&#xD;
Absence of pathology exacerbation visible by radiological results (comparison with Day 0)&#xD;
Absence of orthopedic surgery or amputation of the foot infected initially.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound healing</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison in each group of patients of the time needed for a complete wound healing (with epithelial wound closure) and maintained 28 days minimum of the initial site of injury caused by osteomyelitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of infection</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of reinfection at the initial site in each group of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New infection at the initial site</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of occurrence of a new wound after healing, on the same site initially traited in each group of patients. A new wound is defined by a skin injury under the malleolus evolving over three weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New infection on the same foot</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of occurrence of a new wound after healing on the same foot but not the same infection site in each group of patients.A new wound is defined by a skin injury under the malleolus evolving over three weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of occurrence of a neuroathropathy (Charcot foot) in each group of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthopedic surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of minor and/or major amputation defined as an amputation below or above the ankle respectively (malleolus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major orthopedic surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of major amputation defined as an amputation above the ankle (malleolus)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Osteomyelitis - Foot</condition>
  <arm_group>
    <arm_group_label>3 weeks antibiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated 3 weeks with appropriate antibiotics after antibiogram evaluation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 weeks antibiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated 6 weeks with appropriate antibiotics after antibiogram evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks</intervention_name>
    <description>Drugs :&#xD;
Rifampin (IP an PO) : 10mg/Kg/12h&#xD;
Ofloxacin (PO) : 200Mg/8h&#xD;
Levofloxacin (PO) : 500mg ot 1g/ twice a day&#xD;
Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains&#xD;
Clindamycin : 600-900mg/8h&#xD;
Fusidic Acid : 500mg/8h&#xD;
Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.&#xD;
Ceftasidim : 2g/8h if Pseud spp ; 2g/12h for others Gram-negative bacilli strains&#xD;
Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient &lt; 80Kg ; one and a half per day if patient &gt; 80Kg.&#xD;
Doxycyclin : 200mg/day&#xD;
Minocyclin : 100mg/8h to 12h&#xD;
Ceftriaxon : 1g to 2g/day in IV, IM or SC&#xD;
Cefotaxim : 1g to 2g/day in IV&#xD;
Pristinamycin : 1g thrice a day</description>
    <arm_group_label>3 weeks antibiotherapy</arm_group_label>
    <arm_group_label>6 weeks antibiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged ≥ 18 years&#xD;
&#xD;
          -  Informed, written consent obtained from patient&#xD;
&#xD;
          -  Patient having the rights to Frenc social insurrance&#xD;
&#xD;
          -  For women of childbearing potential : any effective contraceptive is required&#xD;
&#xD;
          -  Type 1 or 2 diabetic patients&#xD;
&#xD;
          -  Diabetic patients treated non-surgically for an osteomyelitis of the forefoot&#xD;
             affecting only one osteoarticular part/radial supported by adequate diagnostic imaging&#xD;
             and bone biopsy performed through uninfected tissue.&#xD;
&#xD;
          -  Two peripheral pulses or transcutaneous oxygen tension measurement (TcPO2 &gt; 30mmHg) or&#xD;
             ankle brachial index (ABI &gt; 0.9)&#xD;
&#xD;
          -  Patient without antibiotherapy during 2 weeks before D1.&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1C) &lt; 12% ( measured maximum 2 months before D1)&#xD;
&#xD;
          -  Use of offloading boot for diabetic foot is feasible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bone fragmentation, articular destruction requiring bone resection or amputation.&#xD;
&#xD;
          -  Gangrene&#xD;
&#xD;
          -  More than one osteoarticular part/radial affected&#xD;
&#xD;
          -  Contraindication for the use of offloading boot&#xD;
&#xD;
          -  Contraindication for bone biopsy&#xD;
&#xD;
          -  Contraindication for the full course of antibiotics (allergy or based on RCP)&#xD;
&#xD;
          -  Other drug-drug interaction that contraindicated the full course of antibiotics&#xD;
&#xD;
          -  Charcot foot&#xD;
&#xD;
          -  Patient undergoing radiotherapy of chimiotherapy for malignant neoplasms&#xD;
&#xD;
          -  Hepatic insufficiency (ASAT and/or ALAT &gt; 3 times the normal level)&#xD;
&#xD;
          -  Any disease or behaviour making impossible to follow the protocol or difficult to&#xD;
             interpret the results&#xD;
&#xD;
          -  Any disease or context making difficult to allow regular monitoring of the patient&#xD;
&#xD;
          -  Participation in other interventional research during the study&#xD;
&#xD;
          -  Curator or guardianship of patient placed under judicial protection&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric M SENNEVILLE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Tourcoing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric SENNEVILLE, MD, PhD</last_name>
    <phone>+33 320694848</phone>
    <email>esenneville@ch-tourcoing.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solange TREHOUX, PhD</last_name>
    <phone>+33 320684280</phone>
    <email>strehoux@ch-tourcoing.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Aurélien DINH, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Boulogne-sur-Mer</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie LEPAGE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hopitalier Universitaire de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Rozenn LEBERRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Béthune-Beuvry</name>
      <address>
        <city>Béthune</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie NGUYEN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jocelyn MICHON, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Compiègne-Noyon</name>
      <address>
        <city>Compiègne</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amina BOURAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline DEHECQ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lens</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrice DEVEMY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florence BAUDOUX, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHICL Saint-Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas BACLET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHICL Saint-Philibert</name>
      <address>
        <city>Lomme</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas BACLET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ariane SULTAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>David BOUTOILLE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jocelyne M'BEMBA-ILZER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne-Lise MUNIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Roubaix</name>
      <address>
        <city>Roubaix</city>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie PICHENOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gaëtan PROVOST, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alina TONE, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Antibiotic Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomyelitis</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

